NGL Fine Chem Ltd

- The planned Greenfield expansion at Tarapur involves a CAPEX of Rs. 140 crores. - Financial closure for Rs. 120 crores is already in place for this project. - Funding for this includes approximately Rs. 80 crores through debt and Rs. 40 crores through internal accruals. - So far, about Rs. 8 crores have been spent on this project entirely from internal accruals. - There is no mention of any new equity fundraising during this period; focus is on debt and internal accruals for funding expansion.

- Macrotech Brownfield expansion completed last quarter; validation batches ongoing with commercialization expected from the current quarter. - Greenfield expansion at Tarapur underway; civil construction started December with work progressing well. - Tarapur CAPEX revised to Rs. 140 crores (up from earlier Rs. 100 crores), driven by inflation and higher material costs. - Tarapur project will bring 50% capacity addition; expected completion and production start in FY24. - Tarapur CAPEX to be funded through a mix of debt and internal accruals. - Aim to increase outsource production from current 10% to 15% by end of FY23 to stay asset-light and support sales growth. - Continuous debottlenecking and process improvements ongoing for near-term growth. - Despite inflation and global challenges, company continues to invest strategically to maintain market position and cost competitiveness.

- The poultry product business is expected to grow by 100% to 125% in the current year. - Five new molecules in the pipeline are expected to add revenue; two are large volume commodity products with a worldwide market potential of around Rs. 300 crores. - Initial sales target for these new products is Rs. 10-15 crores in the first year, aiming for 10%-15% market share over 3 years. - The company targets about 20%-25% volume growth annually. - Macrotech Brownfield expansion will add Rs. 40-50 crores in sales capacity, expected to contribute from Q2/Q3. - Greenfield expansion at Tarapur will add 50% capacity, aiming for appx. Rs. 200 crores in sales on a Rs. 100 crore investment (revised CAPEX now Rs. 140 crores). - Overall, growth is driven by acquiring more customers, product diversification, and increasing acceptance in the market.

- The company aims for about 20-25% volume growth annually in the veterinary API segment. - Long-term growth story remains strong despite short-term margin pressures due to raw material cost inflation. - New products pipeline includes 5 molecules with more than 5-step synthesis; these are expected to be margin accretive. - Greenfield expansion at Tarapur (Rs. 140 crores capex) will add 50% capacity by FY24, expected to contribute positively to sales and margins. - Macrotech Brownfield expansion completed; expected to add Rs. 40-50 crores in sales with steady margins, impacting revenues within the current fiscal year. - Outsourcing increase from 10% to 15% targeted, aiding near-term growth and cost competitiveness. - Short-term margin challenges expected for 2 more quarters due to elevated input costs and market resistance to price hikes; normalization expected within 6-9 months. - Sustained market share gains and expanded customer base underpin optimistic future growth outlook.

- The next demand for products is expected only in July, as mentioned by Rahul Nachane. - Current booking/orders are valid till July, indicating ongoing orders but with limited advance visibility beyond that. - There is some resistance in the market currently in accepting price increases, so demand is somewhat muted in the short term. - Customers are holding back demand temporarily due to pricing pushback but are expected to return once prices stabilize. - No explicit current orderbook value or exact pending order quantity is disclosed. - Overall, order intake appears steady with adjustments in timing due to pricing dynamics and market conditions.